Consolidated Statement of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues
Revenues	$ 44,915	$ 39,211	$ 32,218
Costs and operating expenses:
Selling, general and administrative expenses	8,993	8,007	6,930
Research and development expenses	1,471	1,406	1,181
Restructuring and other costs	114	197	99
Total costs and operating expenses	36,522	29,183	24,424
Operating income	8,393	10,028	7,794
Interest income	272	43	65
Interest expense	(726)	(536)	(553)
Other income/(expense)	(104)	(694)	(76)
Income before income taxes	7,835	8,841	7,230
Provision for income taxes	(703)	(1,109)	(850)
Equity in earnings/(losses) of unconsolidated entities	(172)	(4)	(3)
Net income	6,960	7,728	6,377
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest	10	3	2
Net income attributable to Thermo Fisher Scientific Inc.	$ 6,950	$ 7,725	$ 6,375
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic (in dollars per share)	$ 17.75	$ 19.62	$ 16.09
Diluted (in dollars per share)	$ 17.63	$ 19.46	$ 15.96
Weighted average shares
Basic (in shares)	392	394	396
Diluted (in shares)	394	397	399
Product revenues
Revenues
Revenues	$ 28,548	$ 30,361	$ 25,306
Costs and operating expenses:
Cost of revenues	14,247	13,594	11,407
Service revenues
Revenues
Revenues	16,367	8,850	6,912
Costs and operating expenses:
Cost of revenues	$ 11,697	$ 5,979	$ 4,807